{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:53:10Z","timestamp":1780465990215,"version":"3.54.1"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immunoglobulin M monoclonal gammopathy of undetermined significance (MGUS) comprises 15-20% of all cases of MGUS. IgM MGUS is distinct from other forms of MGUS in that the typical primary progression events include Waldenstrom macroglobulinaemia and light chain amyloidosis. Owing to its large pentameric structure, IgM molecules have high intrinsic viscosity and precipitate more readily than other immunoglobulin subtypes. They are also more commonly associated with autoimmune phenomena, resulting in unique clinical manifestations. Organ damage attributable to the paraprotein, not fulfilling criteria for a lymphoid or plasma cell malignancy has recently been termed monoclonal gammopathy of clinical significance (MGCS) and encompasses an important family of disorders for which diagnostic and treatment algorithms are evolving. IgM related MGCS include unique entities such as cold haemagglutinin disease, IgM related neuropathies, renal manifestations and Schnitzler\u2019s syndrome. The diagnostic approach to, and management of these disorders differs significantly from other categories of MGCS. We describe a practical approach to the evaluation of these patients and our approach to their treatment. We will also elaborate on the key unmet needs in IgM MGCS and highlight potential areas for future research.<\/jats:p>","DOI":"10.3389\/fonc.2022.905484","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T12:54:01Z","timestamp":1654779241000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Immunoglobulin M Monoclonal Gammopathies of Clinical Significance"],"prefix":"10.3389","volume":"12","author":[{"given":"Louis-Pierre","family":"Girard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinnie Yentia","family":"Soekojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"de Mel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1365-2141.2009.07807.x","article-title":"UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): Guidelines for the Investigation of Newly Detected M-Proteins and the Management of Monoclonal Gammopathy of Undetermined Significance (MGUS)","volume":"147","author":"Bird","year":"2009","journal-title":"Br J Haematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.002","article-title":"IgM Monoclonal Gammopathy of Undetermined Significance and Smoldering Waldenstr\u00f6m's Macroglobulinemia","volume":"9","author":"Kyle","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.3390\/cancers12061688","article-title":"Immunoglobulin M Paraproteinaemias","volume":"12","author":"Girard","year":"2020","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering (Asymptomatic) Multiple Myeloma: IMWG Consensus Perspectives Risk Factors for Progression and Guidelines for Monitoring and Management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000122","article-title":"Monoclonal Gammopathies of Clinical Significance","volume":"2020","author":"Dispenzieri","year":"2020","journal-title":"Hematology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2005.n.012","article-title":"Clinical Characteristics and Outcome of Immunoglobulin M-Related Disorders","volume":"5","author":"Cesana","year":"2005","journal-title":"Clin Lymphoma"},{"key":"B7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The Evaluation of Monoclonal Gammopathy of Renal Significance: A Consensus Report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal Gammopathy of Clinical Significance: A Novel Concept With Therapeutic Implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.12688\/f1000research.12880.1","article-title":"Advances in the Understanding of IgM Monoclonal Gammopathy of Undetermined Significance","volume":"6","author":"Paludo","year":"2017","journal-title":"F1000Research"},{"key":"B10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12883-016-0532-4","article-title":"Paraproteinemic Neuropathy: A Practical Review","volume":"16","author":"Rison","year":"2016","journal-title":"BMC Neurol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"577725","DOI":"10.1016\/j.jneuroim.2021.577725","article-title":"Anti-MAG Neuropathy: From Biology to Clinical Management","volume":"361","author":"Steck","year":"2021","journal-title":"J Neuroimmunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.02.003","article-title":"Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management","volume":"92","author":"Chaudhry","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/jnnp-2017-316715","article-title":"Anti-MAG Antibodies in 202 Patients: Clinicopathological and Therapeutic Features","volume":"89","author":"Svahn","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007092","article-title":"CANOMAD: A Neurological Monoclonal Gammopathy of Clinical Significance That Benefits From B-Cell\u2013Targeted Therapies","volume":"136","author":"Le Cann","year":"2020","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.10.1968","article-title":"The Clinical and Laboratory Features of Chronic Sensory Ataxic Neuropathy With Anti-Disialosyl IgM Antibodies","volume":"124","author":"Willison","year":"2001","journal-title":"Brain"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-719773","article-title":"How I Treat Cryoglobulinemia","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.057620","article-title":"Clinical Spectrum of Cryoglobulinaemic Neuropathy","volume":"76","author":"Gemignani","year":"2005","journal-title":"J Neurology Neurosurg Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14492","article-title":"Investigation and Management of IgM and Waldenstr\u00f6m-Associated Peripheral Neuropathies: Recommendations From the IWWM-8 Consensus Panel","volume":"176","author":"D'Sa","year":"2017","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.Suppl.46","article-title":"Human Immunoglobulin Treatment of Multifocal Motor Neuropathy and Polyneuropathy Associated With Monoclonal Gammopathy","author":"Leger","year":"1994","journal-title":"J neurol neurosurg Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.6.9.1267","article-title":"Rituximab in the Treatment of Peripheral Neuropathy Associated With Monoclonal Gammopathy","volume":"6","author":"Zivkovi\u0107","year":"2006","journal-title":"Expert Rev Neurother"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20244","article-title":"Rituximab Treatment of an IgM Monoclonal Autonomic and Sensory Neuropathy","volume":"31","author":"Goldfarb","year":"2005","journal-title":"Muscle Nerve"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1212\/NXI.0000000000001109","article-title":"Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy: Retrospective Study","volume":"9","author":"H\u00e4nggi","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-846816","article-title":"Acute Hyperviscosity: Syndromes and Management","volume":"132","author":"Gertz","year":"2018","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111213252105","article-title":"Plasma Exchange in Polyneuropathy Associated With Monoclonal Gammopathy of Undetermined Significance","volume":"325","author":"Dyck","year":"1991","journal-title":"New Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.66.5.575","article-title":"Successful Treatment of IgM Paraproteinaemic Neuropathy With Fludarabine","volume":"66","author":"Wilson","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/jdv.13847","article-title":"Monoclonal Gammopathy of Cutaneous Significance: Review of a Relevant Concept","volume":"31","author":"Lipsker","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.19-3-224","article-title":"Pyoderma Gangrenosum - A Guide to Diagnosis and Management\u2002Clinical Medicine","volume":"19","author":"George","year":"2019","journal-title":"Lond Engl"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.07.039","article-title":"Paraprotein Deposits in the Skin","volume":"77","author":"Alegr\u00eda-Landa","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1186\/1750-1172-5-38","article-title":"The Schnitzler Syndrome","volume":"5","author":"Lipsker","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2012.01983.x","article-title":"Cutaneous Macroglobulinosis: A Case Series","volume":"39","author":"Camp","year":"2012","journal-title":"J Cutan Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810366","article-title":"Molecular Genetic Investigation, Clinical Features, and Response to Treatment in 21 Patients With Schnitzler Syndrome","volume":"131","author":"Rowczenio","year":"2018","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.588322","article-title":"Cytokine Signature in Schnitzler Syndrome: Proinflammatory Cytokine Production Associated to Th Suppression","volume":"11","author":"Masson Regnault","year":"2020","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13023-019-1117-2","article-title":"Schnitzler\u2019s Syndrome - A Novel Hypothesis of a Shared Pathophysiologic Mechanism With Waldenstr\u00f6m\u2019s Disease","volume":"14","author":"van Leersum","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.10.004","article-title":"Cryoglobulinemic Vasculitis and Skin Ulcers. Our Therapeutic Strategy and Review of the Literature","volume":"44","author":"Giuggioli","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.10.031","article-title":"Complete Remission in 3 of 3 Anti-IL-6-Treated Patients With Schnitzler Syndrome","volume":"129","author":"Krause","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019031914","article-title":"Pathophysiology and Management of Monoclonal Gammopathy of Renal Significance","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"key":"B38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3324\/haematol.2013.091702","article-title":"Primary Cold Agglutinin-Associated Lymphoproliferative Disease: A B-Cell Lymphoma of the Bone Marrow Distinct From Lymphoplasmacytic Lymphoma","volume":"99","author":"Ulla","year":"2014","journal-title":"Haematologica"},{"key":"B39","doi-asserted-by":"publisher","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and Treatment of Autoimmune Hemolytic Anemia in Adults: Recommendations From the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2033982","article-title":"Autoimmune Hemolytic Anemias","volume":"385","author":"Berentsen","year":"2021","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000036","article-title":"Defining Autoimmune Hemolytic Anemia: A Systematic Review of the Terminology Used for Diagnosis and Treatment","volume":"3","author":"Hill","year":"2019","journal-title":"Blood Adv"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-474437","article-title":"Cold Agglutinin Disease","volume":"122","author":"Swiecicki","year":"2013","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003809","article-title":"How I Treat Cold Agglutinin Disease","volume":"137","author":"Berentsen","year":"2021","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1046\/j.1365-2141.2001.03078.x","article-title":"Favourable Response to Therapy With the Anti-CD20 Monoclonal Antibody Rituximab in Primary Chronic Cold Agglutinin Disease","volume":"115","author":"Berentsen","year":"2001","journal-title":"Br J Haematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine Plus Rituximab for Chronic Cold Agglutinin Disease: Results of a Nordic Prospective Multicenter Trial","volume":"130","author":"Berentsen","year":"2017","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in Cold Agglutinin Disease","volume":"384","author":"R\u00f6th","year":"2021","journal-title":"New Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-018-0009-4","article-title":"Cryoglobulinaemia","volume":"4","author":"Roccatello","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2009.02177.x","article-title":"Mechanisms Underlying Acquired Von Willebrand Syndrome Associated With an IgM Paraprotein","volume":"39","author":"Mayerhofer","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000052","article-title":"Lymphoplasmacytic Lymphoma Exposed by Haemoptysis and Acquired Von Willebrand Syndrome","volume":"25","author":"Coucke","year":"2014","journal-title":"Blood Coagulation Fibrinolysis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1053\/beha.2001.0141","article-title":"Acquired Von Willebrand Syndromes: Clinical Features, Aetiology, Pathophysiology, Classification and Management","volume":"14","author":"Michiels","year":"2001","journal-title":"Best Pract Res Clin Haematol"},{"key":"B51","article-title":"Treatment of Acquired Von Willebrand Syndrome in Patients With Monoclonal Gammopathy of Uncertain Significance: Comparison of Three Different Therapeutic Approaches","volume":"92","author":"Federici","year":"1998","journal-title":"Blood J Am Soc Hematol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"9862620","DOI":"10.1155\/2017\/9862620","article-title":"Acquired Von Willebrand Syndrome in IgM Monoclonal Gammopathy as the Presentation of Lymphoplasmacytic Lymphoma","volume":"2017","author":"Wolfe","year":"2017","journal-title":"Case Rep Hematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06633.x","article-title":"Prevalence and Clinical Characteristics of Immune Thrombocytopenic Purpura in a Cohort of Monoclonal Gammopathy of Uncertain Significance","volume":"138","author":"Rossi","year":"2007","journal-title":"Br J Haematol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbacli.2016.05.004","article-title":"Autoimmune Manifestations in Patients With Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance","volume":"6","author":"Shimanovsky","year":"2016","journal-title":"BBA Clin"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","article-title":"AL Amyloidosis: From Molecular Mechanisms to Targeted Therapies","volume":"2017","author":"Merlini","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0667-6","article-title":"IgM AL Amyloidosis: Delineating Disease Biology and Outcomes With Clinical, Genomic and Bone Marrow Morphological Features","volume":"34","author":"Sidana","year":"2019","journal-title":"Leukemia"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-310704","article-title":"Light-Chain Cardiac Amyloidosis: Strategies to Promote Early Diagnosis and Cardiac Response","volume":"103","author":"Grogan","year":"2017","journal-title":"Heart"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.03.036","article-title":"Amyloidosis and Bleeding: Pathophysiology, Diagnosis, and Therapy","volume":"47","author":"Sucker","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.05.002","article-title":"The Clinical Spectrum of IgM Monoclonal Gammopathy: A Single Center Retrospective Study of 377 Patients","volume":"46","author":"Cao","year":"2016","journal-title":"Leuk Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2017.09.012","article-title":"The Peripheral Neuropathies of POEMS Syndrome and Castleman Disease","volume":"32","author":"Mauermann","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25495","article-title":"POEMS Syndrome: 2019 Update on Diagnosis, Risk-Stratification, and Management","volume":"94","author":"Dispenzieri","year":"2019","journal-title":"Am J Hematol"},{"key":"B62","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0076-5","article-title":"Waldenstr\u00f6m Macroglobulinemia Treatment Algorithm 2018","volume":"8","author":"Gertz","year":"2018","journal-title":"Blood Cancer J"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21845","article-title":"IgM Multiple Myeloma: Disease Definition, Prognosis, and Differentiation From Waldenstrom's Macroglobulinemia","volume":"85","author":"Schuster","year":"2010","journal-title":"Am J Hematol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457101","article-title":"Prevalence and Clinical Significance of the MYD88 (L265P) Somatic Mutation in Waldenstrom's Macroglobulinemia and Related Lymphoid Neoplasms","volume":"121","author":"Varettoni","year":"2013","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806463","article-title":"First Report of Ibrutinib in IgM-Related Amyloidosis: Few Responses, Poor Tolerability, and Short Survival","volume":"131","author":"Pika","year":"2018","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1182384","DOI":"10.1155\/2022\/1182384","article-title":"Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenstr\u00f6m's Macroglobulinemia)","volume":"2022","author":"Bou Zerdan","year":"2022","journal-title":"Adv Hematol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30224-6","article-title":"Consensus Treatment Recommendations From the Tenth International Workshop for Waldenstr\u00f6m Macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00555","article-title":"Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstr\u00f6m Macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J Clin Oncol"},{"key":"B71","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.161.8.4091","article-title":"Production of IgM Hexamers by Normal and Autoimmune B Cells: Implications for the Physiologic Role of Hexameric IgM","volume":"161","author":"Hughey","year":"1998","journal-title":"J Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2011.08.018","article-title":"Hexameric Immunoglobulin M in Humans: Desired or Unwanted","volume":"77","author":"Petru\u0161i\u0107","year":"2011","journal-title":"Med Hypotheses"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.905484\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T20:19:17Z","timestamp":1675801157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.905484\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":72,"alternative-id":["10.3389\/fonc.2022.905484"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.905484","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"article-number":"905484"}}